A Full Cycle
of Mental Wellness

From Research to Remedy

MINDCURE identifies, innovates, and commercializes new methods to promote Mental Wealth™. Psychedelics can heal a world in pain and MINDCURE is leading the way.

How We Elevate Mental Wealth

MINDCURE isn’t your typical pharma company.

We’re revolutionizing mental health treatment options by combining these intimately related spheres:

Our Technology

Meet our cutting-edge digital therapeutics platform optimizing healing for mental health clinicians and patients

Our Research

Discover how we identify opportunities and develop treatment pathways


Digital Therapeutics

Making Mental Wealth Accessible

iSTRYM is a first-of-its-kind software application that optimizes the healing journey for both patients and clinicians — before, during, and after therapy sessions. By bringing together a variety of healing solutions, such as convenient user dashboards, guided mindfulness practices, intelligent data analysis, and more, iSTRYM optimizes therapy.


Access a robust repository of treatment protocols and care packages

Individualize care with digitized, data-driven analytics

Monitor client status before, during, and after sessions for deeper insights that don’t interrupt care

Empowering Individuals

Own your mental wellness journey with automated support, personalized to your custom care needs and preferences

Explore guided practices to elevate your mindset

Our Research

MINDCURE’s research team is constantly uncovering opportunities to promote healing. We develop psychedelic treatment protocols and synthesize compounds for commercial use in clinical studies that show therapeutic potential.

The Desire Project

Using MDMA-Assisted Psychotherapy to Help Women Overcome Lack of Desire

Hypoactive Sexual Desire Disorder (HSDD) is a common female sexual disorder characterized by persistent low sexual desire and emotional distress that are not attributable to an existing medical condition or relationship issue.

In the U.S. alone, HSDD affects an estimated 9.5 million premenopausal women.

Learn more about the research MINDCURE is doing to address this under researched and under treated condition.

The Ibogaine Project

Sustainable supply of synthesized ibogaine

MINDCURE is manufacturing synthetic ibogaine in order to provide researchers and clinicians with the resources they need to promote healing.

Indications include addiction, migraines, cluster headaches, neuropathic pain, treatment-resistant mood disorders, and more.

There is a growing need for a sustainable and reliable supply of ibogaine.

Identifying Opportunities

Our technology confirms our starting point by discovering target receptors, methods, and opportunities for healing.

Product Discovery & Lead Optimization

We analyze the molecular structures of psychedelic compounds, such as ibogaine, and synthesize novel substances.


We conduct clinical trials with novel, synthetic, and classic psychedelics to discover new indications and shape a baseline for treatment protocols.

From pain point to product, our team continues to substantiate decades of scientific evidence around psychedelics for their potential in mental health treatments.

MINDCURE is manufacturing synthetic ibogaine in order to provide researchers and clinicians with the resources they need to promoting healing related to:


Neuropathic pain


Cluster headaches

Treatment-resistant mood disorders

Cluster Headaches
Neuropathic Pain
Treatment-Resistant Mood Disorders

Our Products

Wellness products like you’ve never seen. We’re promoting mental health and mental wealth with nootropics, adaptogens, and more.

We’re never idle — between researching, identifying, and perfecting new formulations with therapeutic benefits.

Invest in the Moment

Why invest in psychedelic therapy?

971 million

People worldwide currently suffer from a mental disorder


The number of registered mental health treatment facilities in the U.S. as of 2019 that could benefit from a digital therapeutics platform like iSTRYM2

$56 billion

The projected global market for digital therapeutics by 20251

90% efficacy

In a recent study done at the University of California, San Diego, 90% of participants that had undergone ibogaine treatment showed reduced withdrawal symptoms and cravings, while abstaining from drug use for at least one week. 25% of participants showed an average abstinence period of 3.5 years post-treatment3

Be in the know when we release a new product — join our mailing list.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our Team

See who's executing our ground-breaking approaches to psychedelic treatment and technology. We’re industry experts in biotech, life sciences, data research, new product discovery, integrative technology, biomedical innovation, and health care. Our team is at the forefront of scientific discovery.

Philip Tapley

Interim CEO & Chairman of the Board of Directors

Jason Pamer


Michael Wolfe

Chief Financial Officer

Stephen Inouye


No items found.
Meet the rest of the team
Meet the rest of the team